AU2020277230A1 — Angiotensin ll alone or in combination for the treatment of hypotension

USPTO Abstract

An embodiment of the present invention relates, e.g., to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose 5 equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-2.0 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min 0 norepinephrine or less. WO 2015/095535 PCT/US2014/071186 1/4 Start Study Drug/Placebo at 20 ng/kg/min for 1 hr s Is NorEpis>p10 mcg/min? r -j Yes No Increase dose of N NorEpi I 5 5-10 mcgmin? AAngietensin||lPPlacebo by 10 ng/kg/min for I hr Yes and reassess NorEpi dose Is Nr~pi< 5mcg/inDo not change the dose of Is Nr~p< 5 cg/inAngiotensin illPlacebo for one hour and reassess Yes MAP and NorEpi requirements in 1-hr Decrease dose of Angiotensin Il/Placebo by 10 ng/kg/min for 1hr and re-assess NorEpi dose in 1 hour. Dose de-escalation continues until the drug dose is10 ng/kg/min When achieving the minimal study drug infusion rate of 10 ng/kg/min, is MAP>80 or NorEpi weaned off? |~ y Mintain the study drug Y Iinfusionrate of 10ngkg/min Decrease dose of Angiotensinll/Placebo to 5 ng/kg/min for 30 mins and reassess NorEpi dose Yes If MAP>80, titrate off the drug FIG. 1